COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,666 Articles (22,913 medRxiv, 8,753 bioRxiv)

Most recent first Previous |  Page 3001: Articles 30001-30010  | Next

Multidrug treatment with nelfinavir and cepharanthine against COVID-19
Ohashi, H., Watashi, K., Saso, W., Shionoya, K., Iwanami, S., Hirokawa, T., Shirai, T., Kanaya, S., Ito, Y., Kim, K. S., Nishioka, K., Ando, S., Ejima, K., Koizumi, Y., Tanaka, T., Aoki, S., Kuramochi, K., Suzuki, T., Maenaka, K., Matano, T., Muramatsu, M., Saijo, M., Aihara, K., Iwami, S., Takeda, M., McKeating, J., Wakita, T.
10.1101/2020.04.14.039925 — Posted: 2020-04-15
TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets
Bestle, D., Heindl, M. R., Limburg, H., Van Lam van, T., Pilgram, O., Moulton, H., Stein, D. A., Hardes, K., Eickmann, M., Dolnik, O., Rohde, C., Becker, S., Klenk, H.-D., Garten, W., Steinmetzer, T., Bottcher-Friebertshauser, E.
10.1101/2020.04.15.042085 — Posted: 2020-04-15 Discussion: Offsite
Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics
Gassen, N. C., Papies, J., Bajaj, T., Dethloff, F., Emanuel, J., Weckmann, K., Heinz, D. E., Heinemann, N., Lennarz, M., Richter, A., Niemeyer, D., Corman, V. M., Giavalisco, P., Drosten, C., Muller, M. A.
10.1101/2020.04.15.997254 — Posted: 2020-04-15 Discussion: Onsite | Offsite
Genetic Variability of Human Angiotensin-Converting Enzyme 2 (hACE2) Among Various Ethnic Populations
Li, Q., Cao, Z., Rahman, P.
10.1101/2020.04.14.041434 — Posted: 2020-04-15
Phylogenetic Analysis of the Novel Coronavirus Reveals Important Variants in Indian Strains
Joshi, A., Paul, S.
10.1101/2020.04.14.041301 — Posted: 2020-04-15
The FDA-approved gold drug Auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells
Rothan, H., Stone, S., Natekar, J., Kumari, P., Arora, K., Kumar, M.
10.1101/2020.04.14.041228 — Posted: 2020-04-15 Discussion: Onsite | Offsite
The global population of SARS-CoV-2 is composed of six major subtypes
Morais Junior, I. J., Costa Polveiro, R., Souza, G. M., Bortolin, D. I., Sassaki, F. T., Lima, A. T. M.
10.1101/2020.04.14.040782 — Posted: 2020-04-15 Discussion: Onsite
COVID-19 Knowledge Graph: a computable, multi-modal, cause-and-effect knowledge model of COVID-19 pathophysiology
Domingo-Fernandez, D., Baksi, S., Schultz, B. T., Gadiya, Y., Karki, R., Raschka, T., Ebeling, C., Hofmann-Apitius, M., Kodamullil, A. T.
10.1101/2020.04.14.040667 — Posted: 2020-04-15
Bayesian Adaptive Clinical Trials for Anti-Infective Therapeutics during Epidemic Outbreaks
Xu, Q., Chaudhuri, S., Xiao, D., Lo, A. W.
10.1101/2020.04.09.20059634 — Posted: 2020-04-14
Impact of COVID-19 pandemic on severity of illness and resources required during intensive care in the greater New York City area
Badawi, O., Liu, X., Berman, I., Amelung, P. J., Doerfler, M., Chandra, S.
10.1101/2020.04.08.20058180 — Posted: 2020-04-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).